An Educational Intervention for Patients With Bladder Cancer
NCT01915121 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 43
Last updated 2017-08-04
Summary
The study main objectives are to enhance treatment decision making and improve quality of life and post-treatment health care among patients diagnosed with invasive bladder cancer.
Bladder cancer (BL Ca) is the 5th most commonly diagnosed cancer in the US . BL Ca is more common among men than women and 90% of all patients are over the age of 55. Surgery to remove the bladder followed by one of three diversion techniques (i.e., ileal conduit, continent reservoir, and neobladder) is the standard therapy following invasive bladder cancer. The emotional, functional, physical, and social impact of invasive Bl Ca treatment on patients' QOL and adjustment can be devastating. This impact significantly varies by treatment option. Treatment decision making in for BL Ca is difficult at best and potentially susceptible to a number of cognitive and affective factors (e.g., patients' emotional reaction, values, and expectations). Thus, in addition to adjusting to a potential life-threatening disease, having to cope with uncertainty about the efficacy and outcomes of different treatment options adds to the overall distress and may impair effective decision-making. In spite of increasing efforts in health communication and patient education, no study has examined treatment decision making among invasive bladder patients or has provided an educational intervention to facilitate treatment decision making among this population. To this end, and guided by the Self-Regulation theory (SRT) that emphasizes the role of cognitive and emotional factors in decision making, we have designed and pilot tested the acceptability of a preliminary educational and training experiential intervention (ETE) to address this gap in the literature. The ETE intervention uses new and innovative educational strategies and methods to educate patients about their treatment options and to facilitate their treatment decision making.
Conditions
Interventions
- BEHAVIORAL
-
Education Intervention
1-hour educational and training sessions. In this session, participant will be provided with information about bladder cancer treatment options, and training tools directly related to Bladder Cancer. In 4 to 5 days following the session, participants will be asked to schedule the time to talk about experience and how the intervention affects their treatment decision making and to answer some questions about the educational and training session they attended. Participants will then be called after 1-month, 3-month, and 6-month after their bladder cancer treatment to follow up.
- BEHAVIORAL
-
Nutrition Intervention
1-hour educational and training sessions. In this session, participant will be provided with nutrition information directly related to Bladder Cancer recovery. In 4 to 5 days following the session, participants will be asked to schedule the time to talk about experience and how the intervention affects their treatment decision making and to answer some questions about the educational and training session they attended. Participants will then be called after 1-month, 3-month, and 6-month after their bladder cancer treatment to follow up.
Sponsors & Collaborators
-
Icahn School of Medicine at Mount Sinai
lead OTHER
Principal Investigators
-
Nihal E Mohamed, PhD · Icahn School of Medicine at Mount Sinai
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-09-30
- Primary Completion
- 2017-06-30
- Completion
- 2017-06-30
Countries
- United States
Study Locations
More Related Trials
-
Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study
NCT06350734 ·Status: ACTIVE_NOT_RECRUITING
-
Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2
NCT07225127 ·Status: RECRUITING
-
Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments
NCT06138561 ·Status: RECRUITING
-
Decision Making for Urinary Diversion in Patients With Bladder Cancer
NCT05111639 ·Status: COMPLETED
-
Bladder Cancer Patient-Reported Outcomes
NCT01090388 ·Status: COMPLETED
-
Personalized Urine Biomarker for Patients With Bladder Cancer
NCT05467267 ·Status: UNKNOWN
-
Intravesical Ty21a for the Treatment of Patients With Non-muscle-invasive Bladder Cancer (NMIBC)
NCT03421236 ·Status: UNKNOWN ·Phase: PHASE1
-
Recovery Support for Bladder Cancer Patients and Caregivers
NCT04055311 ·Status: COMPLETED ·Phase: NA
-
To Better Understand the Most Important Factors for Patients When They Decide on the Type of Treatment They Receive for Muscle Invasive Bladder Cancer (MIBC).
NCT05236218 ·Status: UNKNOWN
-
Behavioral Dietary Intervention for the Improvement of Bladder Cancer Survivorship
NCT04548193 ·Status: COMPLETED ·Phase: PHASE1
-
The Effect of Telephone-Assisted Smoking Cessation Program in Patients Diagnosed With Non-Muscle Invasive Bladder Cancer
NCT05704231 ·Status: UNKNOWN ·Phase: NA
-
An Education and Navigation Support Tool to Improve Participation in Care Coordination Among Patients With Locally Advanced, Metastatic and Unresectable Bladder Cancer and Their Caregivers
NCT06414317 ·Status: RECRUITING ·Phase: NA
-
Follow-Up of Bladder Cancer Patients From the New England Study of Environment and Health
NCT00776178 ·Status: COMPLETED
-
Bacillus of Calmette and Guerin (BCG) Versus Gemcitabine For Intravesical Therapy In High Risk Superficial Bladder Cancer
NCT00696579 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Immunological Response of Bladder Cancer Patients Under BCG
NCT04806178 ·Status: COMPLETED ·Phase: PHASE3
-
Image-Guided Radiation Therapy for Bladder-Cancer Patients Undergoing Radiotherapy and Concurrent Gemcitabine Chemotherapy
NCT01104350 ·Status: COMPLETED ·Phase: PHASE1
-
Intravesical Gemcitabine Instillation Followed by Transurethral Resection for the Treatment of Patients With Superficial Bladder Cancer at Low Risk.
NCT00191711 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Weekly Radiotherapy for Bladder Cancer
NCT01810757 ·Status: COMPLETED ·Phase: NA
-
Skipping BCG for T1a Urinary Bladder Tumor.
NCT04298073 ·Status: UNKNOWN
-
The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer
NCT01697306 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Scheduled Intravesical Gemcitabine Versus Intravesical BCG for Intermediate and High Risk Non Muscle Invasive Bladder Cancer: A Prospective, Randomized Study
NCT05626101 ·Status: RECRUITING ·Phase: NA
-
Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer
NCT06488222 ·Status: RECRUITING ·Phase: PHASE2
-
Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy
NCT06972615 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
The Impact of Late Effects After Treatment for Bladder Cancer on Quality of Life
NCT05195515 ·Status: ENROLLING_BY_INVITATION
-
Sexual Function in Patients Suspected of Non-muscle Invasive Bladder Cancer
NCT02381912 ·Status: COMPLETED